Phaseline

Companies › Azafaros

Azafaros: clinical trials, targets and expected readouts

1 active drug program in 4 registered trials: 3 Phase 3, 1 Phase 2; Metabolic and endocrine; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Nizubaglustat (AZ-3102)
Glucosidase inhibitor
GBA, UGCGPhase 3Gangliosidoses, GM2; Niemann-Pick Type C Disease; GM2 GangliosidosisJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07399704Nizubaglustat (AZ-3102)Phase 2GM2 GangliosidosisMetabolic and endocrineJun 2027
NCT07082543Nizubaglustat (AZ-3102)Phase 3Gangliosidoses, GM2Metabolic and endocrineFeb 2028
NCT07054515Nizubaglustat (AZ-3102)Phase 3Niemann-Pick Type C DiseaseMetabolic and endocrineMay 2028
NCT07082725Nizubaglustat (AZ-3102)Phase 3Niemann-Pick Type C DiseaseMetabolic and endocrineMay 2028

Targets

GBA (1) UGCG (1)

Companies with the same targets

Lingyi Biotech Spur Therapeutics Prevail Therapeutics Bial R&D Investments Amicus Therapeutics Sanofi Idorsia Pharmaceuticals

Companies built like this

Fresenius Kabi Renibus Therapeutics Chendu DIAO Pharmaceutical Group Kowa Company Waterstone Pharmaceutical (Wuhan)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.